AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38421404 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy
Number of subjects: 239
Study 38421404 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with rituximab
Number of subjects: 239
Study 38421404 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with obinutuzumab
Number of subjects: 239
Study 38421404 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific treatment for TLS
Number of subjects: 239
Study 38421421 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS-19.5 mg
Number of subjects: 508
Study 38421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 398
Study 38421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 398
Study 38421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 398
Study 38421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in IGF-1 level
Number of subjects: 398
Study 38421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in GHR level
Number of subjects: 398
Study 38421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in IGFBP-1 level
Number of subjects: 398
Study 38421648 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal behavior change strategies (BCSs) combined with the Otago Exercise Program
Number of subjects: 309
Study 38421648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapersonal behavior change strategies (BCSs) combined with the Otago Exercise Program
Number of subjects: 309
Study 38421648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapersonal and interpersonal BCSs combined with the Otago Exercise Program
Number of subjects: 309
Study 38421648 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 309
Study 38421649 — intervention group
Group type: EXPERIMENTAL
Intervention: Video telemedicine consultations
Number of subjects: 696
Study 38421649 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultations
Number of subjects: 696
Study 38421662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone or cone-rod dystrophy
Number of subjects: 15
Study 38421662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-rod dystrophy
Number of subjects: 15
Study 38421662 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer nuclear layer thickness
Number of subjects: 15
Study 38421662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataxia severity
Number of subjects: 15
Study 38421679 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 120
Study 38421679 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid injection
Number of subjects: 120
Study 38421679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection
Number of subjects: 120
Study 38421679 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 120
Study 38421679 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 120
Study 38421757 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based acceptance and commitment therapy (iACT)
Number of subjects: 0
Study 38421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensartinib 225 mg orally once daily
Number of subjects: 180
Study 38421881 — intervention group
Group type: EXPERIMENTAL
Intervention: High ctDNA levels evaluated by variant allele frequency (VAF) and haploid genome equivalents per milliliter of plasma (hGE/mL) at baseline
Number of subjects: 180
Study 38421881 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA clearance at 6 weeks
Number of subjects: 180
Study 38421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tumor burden evaluated by the diameter of target lesions
Number of subjects: 180
Study 38421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ALK or TP53 mutation
Number of subjects: 180
Study 38421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate Cox regression analysis
Number of subjects: 180
Study 38421922 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2 mg
Number of subjects: 746
Study 38421922 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2-3 mg
Number of subjects: 746
Study 38421922 — intervention group
Group type: COMPARATOR
Intervention: ADT + placebo
Number of subjects: 746
Study 38421921 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg
Number of subjects: 256
Study 38421921 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg
Number of subjects: 256
Study 38421921 — intervention group
Group type: COMPARATOR
Intervention: Valbenazine (both doses)
Number of subjects: 256
Study 38421921 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impression of TD scores
Number of subjects: 256
Study 38421921 — intervention group
Group type: COMPARATOR
Intervention: Treatment-emergent adverse events
Number of subjects: 256
Study 38422316 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical foot massage
Number of subjects: 71
Study 38422316 — intervention group
Group type: COMPARATOR
Intervention: Control (no applications)
Number of subjects: 71
Study 38422320 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb position sustained isometric task
Number of subjects: 31
Study 38422375 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (education about SDB and PAP, goal setting, troubleshooting, motivational enhancement)
Number of subjects: 63
Study 38422375 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 63
Study 38422375 — intervention group
Group type: COMPARATOR
Intervention: Control (non-directive sleep education)
Number of subjects: 63
Study 38422450 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centred habit-formation intervention
Number of subjects: 151
Study 38422450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 38422473 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (specifics not provided)
Number of subjects: 0
Study 38422473 — intervention group
Group type: COMPARATOR
Intervention: Control (specifics not provided)
Number of subjects: 0
Study 38422496 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (25 mg/kg cefazolin IV up to 1g or clindamycin 10 mg/kg up to 600 mg IV in case of cefazolin allergy)
Number of subjects: 160
Study 38422496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10-mL prefilled syringe of normal saline)
Number of subjects: 160
Study 38422505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension group (n=138)
Number of subjects: 279
Study 38422505 — intervention group
Group type: COMPARATOR
Intervention: No-tension group (n=141)
Number of subjects: 279
Study 38422585 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP501 16 mg/m, cisplatin, nivolumab
Number of subjects: 36
Study 38422585 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP501 25 mg/m, cisplatin, nivolumab
Number of subjects: 36
Study 38422585 — intervention group
Group type: COMPARATOR
Intervention: cisplatin, nivolumab
Number of subjects: 36
Study 38422585 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP501 (unknown dosage), cisplatin, nivolumab
Number of subjects: 36
Study 38422781 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM's EXTEM-CFT
Number of subjects: 60
Study 38422781 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM's FIBTEM-MCF
Number of subjects: 60
Study 38422781 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 60
Study 38422781 — intervention group
Group type: COMPARATOR
Intervention: ROTEM parameters and D-dimer
Number of subjects: 60
Study 38422947 — intervention group
Group type: EXPERIMENTAL
Intervention: DEAR weight management
Number of subjects: 72
Study 38422947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 38422953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-inflammatory Mediterranean dietary intervention
Number of subjects: 27
Study 38423010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-allelic SNF8 variants
Number of subjects: 9
Study 38423010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly affected individuals with hypomorphic variant c.304G>A (p.Val102Ile)
Number of subjects: 9
Study 38423021 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination (0.1 mL intradermal injection)
Number of subjects: 1985
Study 38423021 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intradermal injection of 0.9% saline)
Number of subjects: 1985
Study 38423021 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 1985
Study 38423021 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination
Number of subjects: 1985
Study 38423024 — intervention group
Group type: EXPERIMENTAL
Intervention: 3×3 screening for N gonorrhoeae and C trachomatis
Number of subjects: 1014
Study 38423024 — intervention group
Group type: COMPARATOR
Intervention: Non-screening for N gonorrhoeae and C trachomatis
Number of subjects: 1014
Study 38423030 — intervention group
Group type: EXPERIMENTAL
Intervention: GRPR-targeting radiopharmaceutical
Number of subjects: 100
Study 38423047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) - 23 patients received single-fraction SABR of 26 Gy, 47 patients received 42 Gy in three fractions.
Number of subjects: 70
Study 38423047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 70
Study 38423051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivekimab sunirine at 0.045 mg/kg once every 3 weeks (recommended phase 2 dose)
Number of subjects: 91
Study 38423051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivekimab sunirine at doses of 0.015 mg/kg to 0.450 mg/kg (schedule A)
Number of subjects: 91
Study 38423051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivekimab sunirine (schedule A)
Number of subjects: 91
Study 38423215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cotoretigene toliparvovec (5 × 10^11 vg/mL)
Number of subjects: 29
Study 38423215 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cotoretigene toliparvovec (5 × 10^12 vg/mL)
Number of subjects: 29
Study 38423215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 38423215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cotoretigene toliparvovec
Number of subjects: 29
Study 38423215 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cotoretigene toliparvovec
Number of subjects: 29
Study 38423547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 32114
Study 38423547 — intervention group
Group type: COMPARATOR
Intervention: Mustard oil (MO)
Number of subjects: 32114
Study 38423549 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-Informed Platform for Health intervention
Number of subjects: 24
Study 38423582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based programmes (MBPs)
Number of subjects: 241
Study 38423582 — intervention group
Group type: COMPARATOR
Intervention: Light physical exercise (LE)
Number of subjects: 241
Study 38423700 — intervention group
Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel (ide-cel)
Number of subjects: 386
Study 38423700 — intervention group
Group type: COMPARATOR
Intervention: standard regimens (daratumumab, pomalidomide, and dexamethasone; daratumumab, bortezomib, and dexamethasone; ixazomib, lenalidomide, and dexamethasone; carfilzomib and dexamethasone; or elotuzumab, pomalidomide, and dexamethasone)
Number of subjects: 386
Study 38423752 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 2397
Study 38423752 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2397
Study 38423758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Not specified (observational study)
Number of subjects: 659
Study 38423758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: TNF inhibitors (TNFi) as a time-varying covariate
Number of subjects: 659
Study 38423758 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bone marrow oedema (BME) on MRI of the sacroiliac joints (SIJ)
Number of subjects: 659
Study 38423758 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex, symptom duration >1.5 years, Axial Spondyloarthritis Disease Activity Score ≥2.1, smoking (only in HLA-B27 positives)
Number of subjects: 659
Study 38423758 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 659
Study 38423765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (200 mg in 50 mL 0.9% saline)
Number of subjects: 100
Study 38423765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline identical in appearance and volume)
Number of subjects: 100
Study 38423770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic targets (fasting <90 mg/dL and 1-hour postprandial <120 mg/dL)
Number of subjects: 828
Study 38423770 — intervention group
Group type: COMPARATOR
Intervention: Standard glycaemic targets (fasting <95 mg/dL and 1-hour postprandial <140 mg/dL)
Number of subjects: 828
Study 38423771 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain adaptive cognitive training (CCT) for 12 weeks, 30 min/day, 5 days/week
Number of subjects: 200
Study 38423771 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive cognitive training (active control) for 12 weeks, 30 min/day, 5 days/week
Number of subjects: 200
Study 38423771 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain adaptive cognitive training (CCT)
Number of subjects: 200
Study 38423771 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive cognitive training (active control)
Number of subjects: 200
Study 38423778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation within 6 hours postoperatively
Number of subjects: 1492
Study 38423778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation within 12 hours postoperatively
Number of subjects: 1492
Study 38423778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation within 24 hours postoperatively
Number of subjects: 1492
Study 38423778 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing up by the bed
Number of subjects: 1492
Study 38423778 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking away from the bedside
Number of subjects: 1492
Study 38423778 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with mobilisation within 6 hours
Number of subjects: 1492
Study 38423778 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to mobilisation after major upper abdominal surgery
Number of subjects: 1492
Study 38423814 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of RZV with other vaccines
Number of subjects: 3974
Study 38423814 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of RZV with PPSV23
Number of subjects: 3974
Study 38423866 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 1 × 300-mg tablet
Number of subjects: 150
Study 38423866 — intervention group
Group type: COMPARATOR
Intervention: 3 × 100-mg capsules
Number of subjects: 150
Study 38423866 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 1 × 300-mg tablet in fed state (high-fat meal)
Number of subjects: 150
Study 38423866 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 1 × 300-mg tablet in fasted state
Number of subjects: 150
Study 38423992 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg twice daily
Number of subjects: 0
Study 38423992 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan 30 or 60 mg twice daily
Number of subjects: 0
Study 38423992 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan co-administered with itraconazole
Number of subjects: 0
Study 38423992 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan co-administered with rifampin
Number of subjects: 0
Study 38424099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic
Number of subjects: 72
Study 38424099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 38424224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular braided steel retention wire (0.673 × 0.268 mm) bonded to the lingual surfaces of all mandibular teeth from canine to canine
Number of subjects: 66
Study 38424224 — intervention group
Group type: EXPERIMENTAL
Intervention: Round twisted steel wire (0.406 mm)
Number of subjects: 66
Study 38424224 — intervention group
Group type: COMPARATOR
Intervention: Control group with vacuum-formed retainers only (no wires)
Number of subjects: 66
Study 38424224 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups had vacuum-formed removable retainers in the maxilla
Number of subjects: 66
Study 38424224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular wire
Number of subjects: 66
Study 38424224 — intervention group
Group type: EXPERIMENTAL
Intervention: Round wire
Number of subjects: 66
Study 38424308 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib (450 mg QD) and binimetinib (45 mg BID)
Number of subjects: 0
Study 38424308 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (10 mg) and Bupropion (75 mg)
Number of subjects: 0
Study 38424308 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib (300 mg QD) and cetuximab (400 mg/m2)
Number of subjects: 0
Study 38424319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone resorption markers (C-telopeptide (CTx), Pyridinoline (PYD)) and bone formation markers (C-terminal collagen propeptide (CICP), bone alkaline phosphatase (BAP)) assessed in blood.
Number of subjects: 713
Study 38424319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone biomarkers (CICP, CTX, PYD)
Number of subjects: 713
Study 38424344 — intervention group
Group type: EXPERIMENTAL
Intervention: EBQI (Evidence-Based Quality Improvement)
Number of subjects: 12
Study 38424344 — intervention group
Group type: COMPARATOR
Intervention: Control (no EBQI)
Number of subjects: 12
Study 38424537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg, n=73)
Number of subjects: 200
Study 38424537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=74)
Number of subjects: 200
Study 38424609 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated exercise intervention (16-week group-based, workouts twice a week, endurance and resistance training)
Number of subjects: 324
Study 38424609 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 324
Study 38424616 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of acetylcholine (ACh)
Number of subjects: 60
Study 38424616 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of sodium nitroprusside (SNP)
Number of subjects: 60
Study 38424616 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative peak amplitude at iontophoresis of ACh
Number of subjects: 60
Study 38424616 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI occurrence
Number of subjects: 60
Study 38424744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedically attended RSV episodes
Number of subjects: 993
Study 38424744 — intervention group
Group type: COMPARATOR
Intervention: Medically attended RSV
Number of subjects: 993
Study 38425141 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 148
Study 38425141 — intervention group
Group type: COMPARATOR
Intervention: Oral megestrol acetate (MA) 160 mg
Number of subjects: 148
Study 38425284 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 0.5-2 mg/day
Number of subjects: 120
Study 38425446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral Janus kinase inhibitor)
Number of subjects: 1156
Study 38425462 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery coaching training curriculum (150 hours of training)
Number of subjects: 93
Study 38425462 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery coaching services sustained by 72% of agencies after study period
Number of subjects: 93
Study 38425462 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program completion
Number of subjects: 93
Study 38425473 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG247 Smart Heart Sensor system
Number of subjects: 40
Study 38425504 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC5) administered intravenously every 21 days for 6-9 cycles
Number of subjects: 16
Study 38425785 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency multimodal training
Number of subjects: 28
Study 38425987 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (180 mg/m2) administered in 28-day cycles
Number of subjects: 98
Study 38426292 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen and dexamethasone
Number of subjects: 0
Study 38426292 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38426484 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking fatigability (WF) assessed using the distance walk index (DWI)
Number of subjects: 298
Study 38426484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive fatigability (CF) assessed using the SDMT
Number of subjects: 298
Study 38426484 — intervention group
Group type: COMPARATOR
Intervention: Clinical characteristics comparison between WF and non-WF groups
Number of subjects: 298
Study 38426484 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CF and non-CF groups
Number of subjects: 298
Study 38426479 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccination
Number of subjects: 5000000
Study 38426479 — intervention group
Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 5000000
Study 38426741 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide band of keratinized mucosa (WKM ≥ 2 mm)
Number of subjects: 38
Study 38426741 — intervention group
Group type: COMPARATOR
Intervention: Narrow/no band of keratinized mucosa (NKM < 2 mm)
Number of subjects: 38
Study 38426763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical atherosclerosis (SA) burden (measured by coronary artery calcification scoring (CACS) and peripheral SA burden)
Number of subjects: 712